Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Actinium Pharmaceuticals Inc

Healthcare US ATNM

1.21USD
0.01(0.83%)

Last update at 2026-03-10T20:00:00Z

Day Range

1.191.22
LowHigh

52 Week Range

1.1910.24
LowHigh

Fundamentals

  • Previous Close 1.20
  • Market Cap41.18M
  • Volume32397
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-46.48500M
  • Revenue TTM0.08M
  • Revenue Per Share TTM0.003
  • Gross Profit TTM 1.03M
  • Diluted EPS TTM-1.39

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -33.01700M -24.77400M -22.21500M -21.89905M -23.65396M
Minority interest - - - - -
Net income -31.93000M -24.58400M -22.03700M -21.72666M -23.65396M
Selling general administrative 12.00M 8.08M 6.31M 5.52M 6.73M
Selling and marketing expenses - - - - -
Gross profit 1.03M 1.14M - - 0.00000M
Reconciled depreciation 0.70M 0.52M 0.45M 0.42M 0.05M
Ebit -34.10400M -24.96400M -22.39300M -22.07145M -23.82732M
Ebitda -33.40500M -24.44000M -21.94600M -21.65136M -23.77660M
Depreciation and amortization 0.70M 0.52M 0.45M 0.42M 0.05M
Non operating income net other - - - - -
Operating income -34.10400M -24.96400M -22.39300M -22.07145M -23.82732M
Other operating expenses 35.13M 26.11M 22.39M 22.07M 23.83M
Interest expense -1.08700M 0.19M 0.00000M 0.00000M 0.17M
Tax provision - - - - -
Interest income 1.09M 0.19M 0.18M 0.17M 0.17M
Net interest income 1.09M 0.19M 0.18M 0.17M 0.17M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.08700M -0.19000M -0.17800M -0.17239M 0.17M
Total revenue 1.03M 1.14M 0.00000M 0.00000M 0.00000M
Total operating expenses 35.13M 26.11M 22.39M 22.07M 23.83M
Cost of revenue - - - - 0.00000M
Total other income expense net 1.09M 0.19M 0.18M 0.17M 0.17M
Discontinued operations - - - - -
Net income from continuing ops -33.01700M -24.77400M -22.21500M -21.89905M -23.65396M
Net income applicable to common shares -33.01700M -24.77400M -22.21600M -21.90032M -23.65396M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 81.44M 114.19M 80.39M 66.40M 11.67M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.59M 2.03M 1.92M 1.36M 0.83M
Total liab 45.07M 47.71M 6.84M 5.08M 6.03M
Total stockholder equity 36.38M 66.48M 73.55M 61.32M 5.64M
Deferred long term liab - - - - -
Other current liab -0.54100M -24.87000M 6.53M 4.34M 4.60M
Common stock 0.03M 0.03M 0.02M 0.02M 0.16M
Capital stock 0.03M 0.03M 0.02M 0.02M 0.16M
Retained earnings -337.58300M -288.76500M -255.74800M -230.97400M -208.75756M
Other liab - 35.00M - - -
Good will - - - - -
Other assets 0.00000M 0.30M - 1.16M 0.44M
Cash 76.68M 108.91M 77.83M 63.56M 9.25M
Cash and equivalents - - - - -
Total current liabilities 8.49M 10.63M 6.84M 4.77M 5.34M
Current deferred revenue 35.00M 35.00M - -4.34000M -
Net debt -74.56400M -106.32900M -77.51900M -62.82200M -7.82571M
Short term debt 1.08M 0.50M 0.31M 0.43M 0.75M
Short long term debt - - - - 0.38M
Short long term debt total 2.11M 2.58M 0.31M 0.74M 1.43M
Other stockholder equity 373.93M 355.22M 329.27M 292.27M 214.24M
Property plant equipment - 2.95M 0.64M 1.03M 1.14M
Total current assets 78.26M 110.94M 79.75M 64.92M 10.09M
Long term investments - - - - -
Net tangible assets - 66.48M 73.55M 61.32M 5.64M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 7.95M 10.13M 5.54M 4.34M 4.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -0.23742M
Additional paid in capital - - - - -
Common stock total equity - - 0.02M 0.02M 0.16M
Preferred stock total equity - - - - -
Retained earnings total equity - - -255.74800M -230.97400M -208.75756M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.31M 0.30M 0.06M 0.44M 0.44M
Deferred long term asset charges - - - - -
Non current assets total 3.18M 3.25M 0.64M 1.47M 1.58M
Capital lease obligations 2.11M 2.58M 0.31M 0.74M 1.05M
Long term debt total - - - - 0.15M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.36600M -0.13300M -0.25300M -0.06389M -0.09609M
Change to liabilities 38.60M 1.20M -0.25700M -1.25574M 1.13M
Total cashflows from investing activities -0.36600M -0.13300M -0.25300M -0.06389M -0.09609M
Net borrowings -0.04900M -0.08500M -0.46000M -0.24924M 0.02M
Total cash from financing activities 23.11M 35.22M 76.18M 17.11M 16.98M
Change to operating activities -0.43000M 0.49M -0.84600M -0.02145M 0.10M
Net income -33.01700M -24.77400M -22.21500M -21.89905M -23.65396M
Change in cash 31.39M 14.22M 54.31M -4.41126M -3.68606M
Begin period cash flow 78.22M 64.00M 9.69M 14.10M 17.79M
End period cash flow 109.61M 78.22M 64.00M 9.69M 14.10M
Total cash from operating activities 8.64M -20.86600M -21.61700M -21.46145M -20.57106M
Issuance of capital stock 23.16M 35.30M 76.59M 15.93M 16.98M
Depreciation 0.70M 0.52M 0.45M 0.42M 0.05M
Other cashflows from investing activities - - - - -
Dividends paid - - -0.00100M -0.00127M -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - 35.31M 0.00100M 0.00127M 16.98M
Other cashflows from financing activities -0.36600M 0.00600M 0.05M 1.50M 0.00485M
Change to netincome 2.79M 1.69M 1.25M 1.29M 1.80M
Capital expenditures 0.37M 0.13M 0.25M 0.06M 0.10M
Change receivables - - - - -
Cash flows other operating - -0.50300M -0.84600M -0.02145M 0.10M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 14.22M 54.31M -4.41126M -3.68606M
Change in working capital 38.17M 1.69M -1.10300M -1.27719M 1.23M
Stock based compensation 2.79M 1.69M 1.25M 1.29M 1.80M
Other non cash items - -11.06100M -56.51700M 2.25M 6.14M
Free cash flow 8.28M -20.99900M -21.87000M -21.52534M -20.66715M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATNM
Actinium Pharmaceuticals Inc		 0.01 0.83% 1.21 - 6.84 508.38 1.08 1726.07 -3.6241
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Actinium Pharmaceuticals Inc

100 Park Avenue, New York, NY, United States, 10017

Key Executives

Name Title Year Born
Mr. Sandesh C. Seth M.B.A., M.S., MBA Chairman & CEO 1964
Mr. Steven O'Loughlin BS CFO & Corp. Sec. 1986
Dr. Paul Diamond Esq., Ph.D. VP of Patent & Legal Counsel NA
Dr. David Gould Sr. VP of Corp. Devel. & Corp. Affairs NA
Dr. Bernie Cunningham P.M.P., Ph.D. Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management NA
Dr. Qing Liang VP & Head of Radiation Sciences NA
Dr. Robert N. Daly M.S., Ph.D. VP & Head of Clinical Operations NA
Dr. Mamata Gokhale VP & Global Head of Regulatory Affairs NA
Dr. Avinash Desai M.D. Chief Medical Officer NA
Dr. Arun Swaminathan Ph.D. Chief Bus. Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.